These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 37112836)

  • 21. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data.
    Khan A; Zia T; Suleman M; Khan T; Ali SS; Abbasi AA; Mohammad A; Wei DQ
    J Cell Physiol; 2021 Oct; 236(10):7045-7057. PubMed ID: 33755190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation.
    Huang SW; Miller SO; Yen CH; Wang SF
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
    Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
    EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omicron variant (B.1.1.529) of SARS-CoV-2: understanding mutations in the genome, S-glycoprotein, and antibody-binding regions.
    Bhattacharya M; Sharma AR; Dhama K; Agoramoorthy G; Chakraborty C
    Geroscience; 2022 Apr; 44(2):619-637. PubMed ID: 35258772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations in the receptor-binding domain of human SARS CoV-2 spike protein increases its affinity to bind human ACE-2 receptor.
    Naresh GKRS; Guruprasad L
    J Biomol Struct Dyn; 2023 Apr; 41(6):2368-2381. PubMed ID: 35109768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.
    Chakraborty C; Sharma AR; Bhattacharya M; Lee SS
    Front Immunol; 2022; 13():801522. PubMed ID: 35222380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
    Kumar S; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Oct; 94(10):4780-4791. PubMed ID: 35680610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies.
    Alenquer M; Ferreira F; Lousa D; Valério M; Medina-Lopes M; Bergman ML; Gonçalves J; Demengeot J; Leite RB; Lilue J; Ning Z; Penha-Gonçalves C; Soares H; Soares CM; Amorim MJ
    PLoS Pathog; 2021 Aug; 17(8):e1009772. PubMed ID: 34352039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapidly identifying new coronavirus mutations of potential concern in the Omicron variant using an unsupervised learning strategy.
    Zhao LP; Lybrand TP; Gilbert PB; Payne TH; Pyo CW; Geraghty DE; Jerome KR
    Sci Rep; 2022 Nov; 12(1):19089. PubMed ID: 36352021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uncovering the impact of SARS-CoV2 spike protein variants on human receptors: A molecular dynamics docking and simulation approach.
    Zaheer M; Ali N; Javed H; Munir R; Jamil N
    J Infect Public Health; 2023 Oct; 16(10):1544-1555. PubMed ID: 37566991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant.
    Kim TH; Bae S; Goo S; Myoung J
    J Microbiol Biotechnol; 2023 Dec; 33(12):1587-1295. PubMed ID: 37915256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural and functional insights into the major mutations of SARS-CoV-2 Spike RBD and its interaction with human ACE2 receptor.
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM; Al-Hemaid F; Sami H
    J King Saud Univ Sci; 2022 Feb; 34(2):101773. PubMed ID: 34955621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants.
    da Costa CHS; de Freitas CAB; Alves CN; Lameira J
    Sci Rep; 2022 May; 12(1):8540. PubMed ID: 35595778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.
    Kim S; Liu Y; Lei Z; Dicker J; Cao Y; Zhang XF; Im W
    J Chem Theory Comput; 2021 Dec; 17(12):7972-7979. PubMed ID: 34856802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity.
    Mengist HM; Kombe Kombe AJ; Mekonnen D; Abebaw A; Getachew M; Jin T
    Semin Immunol; 2021 Jun; 55():101533. PubMed ID: 34836774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding Interactions between Receptor-Binding Domain of Spike Protein and Human Angiotensin Converting Enzyme-2 in Omicron Variant.
    Jawad B; Adhikari P; Podgornik R; Ching WY
    J Phys Chem Lett; 2022 May; 13(17):3915-3921. PubMed ID: 35481766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity.
    Liu H; Wei P; Kappler JW; Marrack P; Zhang G
    Front Immunol; 2022; 13():825256. PubMed ID: 35154144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction.
    Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR
    BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.
    Alkhatib M; Salpini R; Carioti L; Ambrosio FA; D'Anna S; Duca L; Costa G; Bellocchi MC; Piermatteo L; Artese A; Santoro MM; Alcaro S; Svicher V; Ceccherini-Silberstein F
    Microbiol Spectr; 2022 Apr; 10(2):e0273221. PubMed ID: 35352942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.